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ABSTRACT
Objective Sarcomeric gene mutation carriers without 
overt left ventricular hypertrophy (G+/LVH−) can harbour 
subclinical changes in cardiovascular structure and 
function that precede the development of hypertrophic 
cardiomyopathy (HCM). We sought to investigate if 
circulating biomarkers of cardiovascular stress and 
collagen metabolism among G+/LVH− individuals, 
measured at rest and following exercise provocation, yield 
further insights into the underlying biology of HCM.
Methods We studied 76 individuals with overt HCM, 
50 G+/LVH− individuals and 41 genotype-negative 
related controls enrolled in a cross-sectional, multicentre 
observational study (HCMNet). Biomarkers of cardiac 
stress (N-terminal pro-B-type natriuretic peptide, NT-
proBNP; high-sensitivity troponin I, hsTnI; soluble ST2) 
and fibrosis (carboxy-terminal propeptide of procollagen 
type I; C-terminal telopeptide of type I collagen; galectin-3; 
periostin) were measured.
Results Individuals with overt HCM had elevated NT-
proBNP and hsTnI compared with G+/LVH− subjects and 
controls at rest, along with an exaggerated increase in 
NT-proBNP and hsTnI in response to exercise. We found 
no detectable differences in resting or exercise-provoked 
biomarker profiles of cardiovascular stress and fibrosis 
among G+/LVH− individuals compared with healthy 
controls despite subtle echocardiographic differences in 
cardiac structure and function.
Conclusion Dynamic exercise testing exaggerated resting 
differences in natriuretic peptides and troponin elevations 
among individuals with overt HCM. In contrast, we found 
no differences in biomarker profiles of cardiovascular 
stress and fibrosis among G+/LVH− individuals compared 
with controls even after maximal exercise provocation. Our 
findings highlight the need for continued investigation into 
early phenotypes of sarcomeric gene mutations and the 
evolution of HCM.
IntROduCtIOn
Hypertrophic cardiomyopathy (HCM) 
is frequently caused by sarcomeric gene 
mutations.1 Due to the autosomal domi-
nant nature of inheritance, each imme-
diate relative of an affected individual has a 
50% chance of carrying the disease-causing 
mutation and potentially developing HCM. 
Therefore, current guidelines recommend 
longitudinal screening of first-degree family 
members of patients with this diagnosis.2 
Most frequently serial clinical evaluation is 
performed; however, genetic testing provides 
the opportunity for more definitive identi-
fication of at-risk relatives, and its use has 
become more widespread. This has resulted 
in a growing population of genotype-posi-
tive individuals without overt left ventricular 
hypertrophy (LVH), and the unique oppor-
tunity to study preclinical phenotypes prior 
to the development of overt clinical manifes-
tations of HCM.3 Prior studies suggest that 
adverse cardiovascular effects of pathogenic 
Key queSTionS
What is already known about this subject?
Sarcomeric gene mutation carriers without overt 
left ventricular hypertrophy (G+/LVH−) can harbour 
subclinical changes in cardiovascular structure and 
function that precede the development of hypertrophic 
cardiomyopathy (HCM).
What does this study add?
Despite subtle subclinical changes in cardiovascular 
structure and function on echocardiography, we found 
no differences in biomarker profiles of cardiovascular 
stress and fibrosis among G+/LVH− individuals 
compared with controls even after maximal exercise 
provocation.
How might this impact on clinical practice?
The potential plasticity of early phenotypic 
manifestations in genotype-positive individuals may 
present future opportunities for prevention in the 
preclinical phase of the disease; however, our findings 
highlight the need for continued investigation into early 
phenotypes of sarcomeric gene mutations and the 
evolution of HCM.
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sarcomeric gene mutations may be at play long before 
the diagnostic clinical phenotype, LVH, is manifest. 
These findings include abnormal myocardial energetics, 
impaired left ventricular (LV) relaxation,4 altered intra-
cellular calcium handling5 and transcriptional upregula-
tion of fibrotic pathways.6 7 The potential plasticity of early 
phenotypic manifestations is supported by animal models 
and clinical data, suggesting that treatment of mutation 
carriers with diltiazem may improve cardiac remodelling 
if administered in the preclinical phase of the disease.5 8 
A number of previous imaging studies focused on geno-
type-positive/LVH-negative (G+/LVH−) individuals have 
demonstrated abnormalities in cardiac structure and 
function.4 9–11 In contrast, there are few studies of circu-
lating biomarkers of cardiovascular stress and collagen 
metabolism in G+/LVH− individuals with conflicting 
results to date.12 13 Therefore in this study, we sought 
to examine specific biomarkers reflecting cardiac stress 
(N-terminal pro-B-type natriuretic peptide, NT-proBNP; 
high-sensitivity troponin I, hsTnI; soluble ST2) and 
fibrosis (carboxy-terminal propeptide of procollagen type 
I, PICP; C-terminal telopeptide of type I collagen, CITP; 
galectin-3; periostin) in a well-characterised genotyped 
population, to attempt to examine potential pathways 
underlying subclinical disease in G+/LVH− individuals.
Lastly, we explored the potential for exercise stress to 
unmask and provoke latent phenotypic traits. Cardio-
pulmonary responses to exercise are predictors of 
outcome among patients with HCM.14 Exercise can 
also enhance detection of cardiovascular dysfunction, 
including abnormal LV strain and twisting reserve in 
HCM.15 Among general cardiology patients referred for 
clinical exercise testing, transient stress-induced isch-
aemia can be detected via ultrasensitive troponin assays.16 
Exercise has not been examined as a means to uncover 
subclinical disease in G+/LVH− individuals. Examining 
such provoked phenotypes is of particular interest to 
further explore mechanisms underlying the formation 
of myocardial fibrosis in HCM, a key feature of clinically 
overt HCM.
Increased replacement and interstitial fibrosis are 
histopathological hallmarks of disease, and the majority 
of adults with HCM have demonstrable late gadolinium 
enhancement on cardiac MRI (CMR).17 Although the 
processes driving scar formation have not been rigorously 
characterised, it is generally considered to be a secondary 
consequence of ischaemic and haemodynamic stressors 
associated with HCM. However, both animal models and 
studies on preclinical human populations have suggested 
that profibrotic pathways are activated early in the patho-
genesis of HCM, prior to the development of LVH.12 A 
potential hypothesis is that the presence of a sarcomeric 
gene mutation may make the myocyte more susceptible 
to injury. Although this susceptibility may not be detect-
able at rest, it may be unmasked by stress. We therefore 
sought to examine provoked phenotypes, as reflected by 
circulating biomarker levels measured after physiolog-
ical stress, to investigate whether exercise testing might 
unmask subclinical phenotypes and a predisposition to 




Participants with overt HCM (G+/LVH+), mutation 
carriers without LVH (G+/LVH−) and healthy geno-
type-negative members of families with known mutations 
were enrolled in a cross-sectional, multicentre observa-
tional study (HCMNet) based at 11 HCM specialty centres 
in the USA (see online supplementary table 1). Geno-
type-positive individuals >5 years of age were included if 
sarcomeric gene mutations were deemed pathogenic or 
likely pathogenic based on segregation, conservation and 
absence from control populations according to standard 
criteria, and reassessed at the time of data analysis.18 All 
genetic testing was performed at Clinical Laboratory 
Improvement Amendments (CLIA_-approved facilities. 
Individuals with overt HCM were defined as sarcomeric 
gene mutation carriers with LV wall thickness ≥12 mm 
in adults >18 years or z-score of ≥3 in subjects under 18 
years of age as previously described.12 Participants were 
deemed G+/LVH− if they were mutation carriers with a 
normal LV wall thickness (defined as maximal thickness 
under the limits above). Healthy genotype-negative rela-
tives with normal LV wall thickness by echocardiogram 
comprised the control population. Participants with 
known hypertension, cardiovascular disease other than 
HCM, prior cardiac surgery or alcohol septal ablation, or 
comorbid conditions potentially altering collagen turn-
over (cirrhosis, liver, pulmonary, renal fibrosis, inflamma-
tory states) were excluded from the study. Individuals >40 
years of age were excluded from G+/LVH− and control 
groups. All participants provided informed consent.
study procedures
Participants underwent comprehensive medical and family 
history, physical exam, and symptom-limited treadmill exer-
cise tolerance testing using a standard Bruce protocol.
Transthoracic echocardiography was performed, 
including two-dimensional, spectral, colour and tissue 
Doppler interrogation. Left atrial (LA), LV dimensions 
and standard parameters of diastolic function, including 
spectral Doppler transmitral early (E) and late (A) 
velocities and E wave deceleration time, were measured 
according to published guidelines.19 Tissue Doppler 
velocities of the lateral, septal, anterior and inferior mitral 
annulus were measured, and global e' velocity calculated 
as the average of these four values.11 Studies were anal-
ysed at a central core laboratory blinded to clinical and 
genotype status. Echocardiographic measurements were 
converted to z-scores (number of SD from the normal 
mean value relative to age or body surface area) due to 
the wide age range in our study cohort.20
CMR with gadolinium enhancement was performed in 
available subjects without contraindications. ECG-gated 
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images were obtained during breath-hold using 1.5T 
or 3T systems using cine steady-state free precession 
imaging for LV function and mass.21 Late gadolinium 
enhancement was determined as previously described, 
and quantified as a percentage of the total LV mass.11 All 
CMR analyses were performed using QMass MR (V.7.4, 
Medis, Leiden, The Netherlands) by a core laboratory 
blinded to clinical and genotype status.
Biomarker assessment
Venous blood samples were obtained at rest, immediately 
after peak exercise and 4 hours post exercise, and serum 
and K3-EDTA plasma samples processed and frozen at 
−80°C for further analysis by the biomarker core labora-
tories (Brigham and Women’s Hospital, Boston, Massa-
chusetts, USA, for NT-proBNP, hsTnI, soluble ST2 and 
galectin-3; University of Navarra, Pamplona, Spain, for 
PICP, CITP, periostin and bone alkaline phosphatase 
(BAP)). Biomarkers were assayed using commercially 
available reagents by personnel blinded to clinical status 
and genotype. For assay details and characteristics, please 
see online supplementary methods.
statistical analysis
Of 193 individuals enrolled in HCMNet, 15 were 
excluded due to genetic variants deemed to be of 
uncertain significance at the time of data analysis, and 
11 individuals were excluded due to missing baseline 
NT-proBNP measures. Baseline characteristics were 
summarised by the three study groups (G+/LVH+, G+/
LVH− and controls) and compared using analysis of 
variance (ANOVA), and pairwise comparisons assessed 
using two-sample t-tests. Bonferroni-corrected p values 
of less than 0.017 were considered statistically significant. 
Biomarkers were log-transformed due to skewed distri-
butions, and values below the detectable threshold were 
set to the lower detection limit (n=11 for NT-proBNP). 
The ratio of PICP/CITP was examined as an integrated 
measure of collagen type I synthesis and degradation.22 
The ratio of PICP to BAP was examined to account 
for bone collagen turnover.23 NT-proBNP, soluble ST2 
(sST2), hsTnI and galectin-3 concentrations before 
and after exercise testing were assessed, and change in 
biomarker concentrations compared between groups. 
Differences between groups were assessed using gener-
alised estimating equations (GEEs) adjusted for age, sex 
and familial correlation using an exchangeable correla-
tion structure.
In exploratory analyses, we compared biomarkers 
before and after exercise between MYH7 and MYBPC3 
mutation carriers, as well as between thick filament 
(MYBPC3, MYH7, MYL2, MYL3) and thin filament muta-
tion carriers (ACTC, TTNT2, TNNI3, TPM1). Correlations 
between biomarkers and measures of cardiac structure 
and function on echocardiography and CMR and exer-
cise testing were assessed using GEE after adjusting for 
age, sex and family correlation. For correlation analyses, 
we accounted for six biomarkers tested, and deemed a 
p value of 0.01 as significant. All analyses were conducted 
using the Statistical Analysis System V.9.3.
Results
A total of 167 genotyped individuals were enrolled in 
this study, including 76 with overt HCM (G+/LVH+), 50 
genotype-positive, LVH-negative individuals (G+/LVH−) 
and 41 genotype-negative controls. Individuals with overt 
HCM were older than G+/LVH− individuals (27±14 vs 
20±11 years, p<0.05; table 1). The majority of individ-
uals with overt HCM were asymptomatic, with 83% New 
York Heart Association class I symptoms and 33% taking 
beta-blockers. Genotyping revealed the majority of muta-
tions were present in MYH7 and MYBPC3 in both G+/
LVH+ and G+/LVH− individuals.
On echocardiography, those with overt HCM had 
larger LA dimensions, smaller LV dimensions, greater LV 
wall thickness and lower mitral annular tissue Doppler 
velocities compared with the G+/LVH− and geno-
type-negative groups (table 1). In contrast to overt HCM, 
differences in LA size, LV dimensions and tissue Doppler 
were less pronounced between G+/LVH− individuals 
and genotype-negative controls. Among a subset of indi-
viduals (n=96) who underwent CMR, late gadolinium 
enhancement was ascertained in 39 G+/LVH+, 29 G+/
LVH− and 23 controls. Among this group, 44% of the 
G+/LVH+ group and none in the G+/LVH− group had 
evidence of late gadolinium enhancement.
Baseline biomarker characterisation of overt and preclinical 
HCM
Individuals with overt HCM had higher baseline 
NT-proBNP (median 137 pg/mL (25th–75th percentile 
60, 569)) compared with G+/LVH− and controls (45 pg/
mL (20, 72) and 32 pg/mL (15, 51), respectively, adjusted 
p for each pairwise comparison <0.0001; table 2). Simi-
larly, those with overt HCM had higher baseline hsTnI 
concentrations (6.3 (3.2, 11.7)) compared with G+/LVH− 
and control groups (1.9 (1.3, 5.0), p=0.008; and 1.4 (0.9, 
2.4) ng/mL, p=0.03, respectively). There were no signif-
icant differences in NT-proBNP or hsTnI between G+/
LVH− and controls. Further, there were no significant 
between-group differences detected for soluble ST2, or 
biomarkers of fibrosis, including galectin-3, PICP, CITP, 
PICP/CITP ratio, BAP, PICP/BAP ratio and periostin (p 
for ANOVA >0.05 for all; table 2).
In exploratory analyses, there were no biomarker 
differences when stratified based on underlying geno-
type (MYH7 (n=46) vs MYBPC3 (n=65) gene mutations) 
(see online supplementary table 2). Similarly, there were 
no significant differences in biomarkers between individ-
uals with thick filament (MYBPC3, MYH7, MYL2, MYL3) 
compared with thin filament mutations (ACTC, TTNT2, 
TNNI3, TPM1; see online supplementary table 3).
exercise effects on biomarkers of cardiovascular stress
Exercise provocation enhanced differences in NT-proBNP 
between the G+/LVH+ group compared with G+/
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LVH− and controls. Specifically, NT-proBNP increased by 
37 pg/mL (27%) in the G+/LVH+ group after exercise, 
compared with a 9 pg/mL increase (20%) in the G+/
LVH− group, and 8 pg/mL increase (25%) in the control 
groups (p<0.0001 for both comparisons; table 2). Simi-
larly, hsTnI increased by 1.5 ng/mL (24%) 4 hours after 
Table 1 Baseline characteristics by study group (n=167)
Overt HCM (n=76) Preclinical HCM (n=50) Control (n=41) p for ANOVA
Clinical characteristics
Age, years 27 (14)*† 20 (11) 17 (8) 0.0002
Women, n (%) 25 (33)*† 28 (56) 24 (56) 0.007
Systolic blood pressure, mm Hg 115 (15) 113 (13) 113 (13) 0.71
Diastolic blood pressure, mm Hg 67 (9) 68 (9) 66 (9) 0.55
Height, cm 168 (18)*† 162 (14) 159 (18) 0.012
Weight, kg 72 (24)*† 62 (18) 58 (21) 0.002
Body surface area, kg/m2 1.83 (0.42)*† 1.67 (0.32) 1.59 (0.39) 0.003
NYHA class, n (%) –
  Class I 63 (83) 50 (100) 41 (100)
  Class II 9 (12) 0 (0) 0 (0)
  Class III 2 (3) 0 (0) 0 (0)
  Class IV 2 (3) 0 (0) 0 (0)
Medication use, n (%) –
  Beta-blocker 25 (33) 0 (0) 0 (0)
  Calcium channel blocker 9 (12) 1 (2) 0 (0)
  ACE inhibitor/ARB 4 (5) 0 (0) 0 (0)
Genetic background, n (%) 0.51
  MYH7 26 (34) 20 (40)
  MYBPC3 39 (51) 26 (52)
  TNNT2 7 (9) 1 (2)
Imaging characteristics
Left atrial diameter, cm 3.7 (0.9)*† 3.0 (0.5)* 2.8 (0.5) <0.0001
LV end-diastolic dimension, z-score −2.6 (1.6)*† −1.8 (1.2)* −1.2 (1.3) <0.0001
LV end-systolic dimension, z-score −2.5 (2.0)*† −1.6 (1.2)* −0.7 (1.4) <0.0001
LV wall thickness, z-score 10.0 (6.7)*† 1.4 (1.3) 1.1 (1.3) <0.0001
LV ejection fraction, % 67 (10)* 67 (8)* 63 (8) 0.048
E/A ratio 1.6 (0.5)*† 2.0 (0.6) 2.0 (0.5) <0.0001
Deceleration time, ms 214 (67)*† 184 (43) 182 (44) 0.003
Mitral valve global e', cm/s 11.3 (3.6)*† 15.2 (1.9)* 16.2 (2.3) <0.0001
Mitral valve global s', cm/s 9.0 (2.0)† 10.3 (1.9) 9.6 (1.8) 0.003
CMR LGE present, n (%) 18 (46) – – –
CMR LGE, % LV mass 5.9 (7.6) NA NA –
Exercise testing
Duration, min 11.6 (3.0) 12.2 (2.2) 11.9 (3.0) 0.48
Peak MET, mL O2/kg/min 13.1 (3.8) 14.3 (2.6) 14.3 (3.2) 0.08
Values are mean (SD) unless otherwise indicated.
Cardiac MRI performed on a subset of n=41 overt HCM, n=32 preclinical HCM and n=23 controls, of whom LGE was assessed in n=39, 29 
and 23 individuals.
*Indicates p<0.05 versus control.
†Indicates p<0.05 versus preclinical HCM.
ANOVA, analysis of variance; ARB, angiotensin receptor blocker; CMR, cardiac MRI; HCM, hypertrophic cardiomyopathy; LGE, late 
gadolinium enhancement; LV, left ventricular; MET, metabolic equivalent; NA, not applicable; NYHA, New York Heart Association; MYH7, 
myosin heavy chain 7; MYBPC3, myosin binding protein C; TNNT2, troponin T2. 
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exercise in the G+/LVH+ group, compared with 0.3 ng/
mL (16%) in the G+/LVH− and 0.4 ng/mL (29%) in 
the control groups, although between-group differences 
were statistically not significant (p for ANOVA 0.22). 
Lastly, soluble ST2 concentrations increased in all three 
groups 4 hours after exercise with no significant between-
group differences (p for ANOVA 0.97).
Biomarkers correlate with cardiac structure and function in 
genotype-positive individuals
Among genotype-positive individuals, NT-proBNP was 
significantly correlated with measures of cardiac struc-
ture and function (figure 1). Specifica lly, NT-proBNP 
was correlated with greater LA diameter, greater LV wall 
thickness, lower mitral e' tissue Doppler velocity and 
greater late gadolinium enhancement by CMR (p<0.001 
for all analyses adjusted for age, sex and familial correla-
tion; table 3).
Similarly, hsTnI was correlated with larger LA diam-
eter, greater LV wall thickness and lower mitral e' velocity 
(p<0.0001 for all). We did not find significant associations 
of soluble ST2 and cardiac structure or function. Lastly, 
galectin-3 concentrations were associated with lower E/A 
ratio (p=0.001), but no other associations with cardiac 
measures were observed (table 3).
dIsCussIOn
Among a young population of sarcomeric gene mutation 
carriers with overt HCM, mutation carriers without LVH 
and healthy genotype-negative members of families with 
known mutations, we found that both NT-proBNP and 
hsTnI were elevated in those with overt HCM. This differ-
ence was further enhanced by dynamic exercise testing, 
with an exaggerated increase in natriuretic peptides in 
response to exercise among individuals with overt HCM. 
Interestingly, despite detectable echocardiographic 
differences in cardiac structure and function among 
mutation carriers and genotype-negative controls, we 
found no significant difference in resting or exercise-pro-
voked biomarker profiles of cardiovascular stress and 
fibrosis among preclinical mutation carriers compared 
with healthy controls.
The growing use of genetic testing has allowed identi-
fication of an intriguing population of individuals who 
carry disease-causing sarcomeric gene mutations at a 
Table 2 Baseline and postexercise cardiovascular biomarkers by study group
Overt HCM (n=76) Preclinical HCM (n=50) Control (n=41) p for ANOVA
Baseline biomarkers, median (25th–75th percentile)
  NT-proBNP, pg/mL 137 (60, 569)*† 45 (20, 72) 32 (15, 51) 0.0005
  High-sensitivity troponin, ng/mL 6.3 (3.2, 11.7)*† 1.9 (1.3, 5.0) 1.4 (0.9, 2.4) 0.03
  Soluble ST2, ng/mL 29.2 (21.5, 37.3) 26.5 (20.0, 35.5) 22.8 (18.5, 31.3) 0.83
  Galectin-3, pg/mL 11.1 (9.7, 13.4) 11.4 (10.2, 12.8) 11.5 (9.7, 12.9) 0.97
  PICP, μg/L 95.4 (67.6, 141.2) 102.5 (84.5, 144.8) 114.9 (73.3, 184.9) 0.94
  CITP, μg/L 4.4 (3.1, 10.0) 6.1 (3.5, 11.5) 5.2 (3.3, 11.4) 0.32
  PICP/CITP ratio 18.7 (12.6, 32.0) 15.8 (10.3, 26.1) 17.6 (13.8, 26.5) 0.09
  BAP, U/L 1.5 (1.1, 2.4) 1.4 (1.1, 2.6) 1.3 (1.0, 1.9) 0.72
  PICP/BAP ratio 57.1 (38.8, 114.6) 68.9 (37.9, 107.8) 87.7 (50.9, 129.0) 0.81
  Periostin 70.5 (56, 93.5) 73.5 (61, 95) 73 (60, 92) 0.99
Immediate or 4-hour postexercise biomarkers, median (25th–75th percentile)
  NT-proBNP, pg/mL 199 (84, 775)*† 54 (27, 93) 41 (23, 77) 0.0004
  Change in NT-proBNP, pg/mL 37 (14, 133)*† 9 (5, 18) 8 (3, 25) 0.0004
  % Change in NT-proBNP (%) 27 (15, 43) 27 (13, 40) 38 (13, 70) 0.08
  4-Hour hsTnI, ng/mL 8.9 (5.4, 18.0)* 2.6 (1.4, 7.2) 2.0 (1.3, 3.8) 0.03
  Change in hsTnI, ng/mL 1.5 (−0.4, 4.5) 0.3 (−0.2, 1.3) 0.4 (−0.2, 1.0) 0.43
  % Change in hsTnI (%) 28 (−4, 67) 17 (−11, 58) 28 (−10, 76) 0.25
  4-Hour soluble ST2, ng/mL 36.1 (26.1, 42.8) 34.5 (25.7, 45.6) 31.5 (24.3, 37.8) 0.66
  Change in sST2, ng/mL 4.5 (0.5, 9.8) 7.9 (2.4, 10.9) 6.3 (2.0, 11.0) 0.68
  % Change in sST2 (%) 17 (1, 36) 28 (10, 42) 19 (13, 41) 0.99
*Indicates p<0.05 versus control.
†Indicates p<0.05 versus preclinical HCM in generalised estimating equations regression analyses accounting for age, sex and familial 
correlation.
ANOVA, analysis of variance; BAP, bone alkaline phosphatase; CITP, C-terminal telopeptide of type I collagen; HCM, hypertrophic 
cardiomyopathy; hsTnI, high-sensitivity troponin I; NT-proBNP, N-terminal pro-B-type natriuretic peptide; PICP, propeptide of procollagen 
type I; sST2, soluble ST2.
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stage when LVH or diagnostic clinical manifestations of 
HCM are absent.24 Although the penetrance of sarco-
meric gene mutations may be variable or incomplete, 
this preclinical population is at high risk for developing 
HCM and therefore provides a unique opportunity 
to examine early phenotypes that may herald adverse 
cardiovascular remodelling that ultimately leads to 
clinical disease. Previous studies have demonstrated 
subclinical abnormalities in diastolic function, myocar-
dial deformation and other structural abnormalities 
among mutation carriers.10 25 26 In addition to differences 
detected on imaging modalities, early transcriptional 
changes and altered myocardial energetics may also be 
at play.6 7 Notably, few studies have examined circulating 
biomarkers in this preclinical population.
Two smaller previous studies have shown no difference 
in resting NT-proBNP concentrations among mutation 
carriers compared with unaffected relatives.11 13 We now 
extend these results to include biomarker profiles obtained 
during exercise testing as a dynamic assessment of cardio-
vascular response to stress, and demonstrate that even with 
provocation, NT-proBNP does not differ among mutation 
carriers and unaffected relatives. In contrast, baseline differ-
ences in NT-proBNP among individuals with overt HCM are 
further unmasked with exercise.
Second, we present a broader range of biomarkers of 
cardiovascular stress and fibrosis among preclinical muta-
tion carriers compared with prior studies. Prior studies 
have demonstrated mixed results with regard to markers 
of collagen metabolism among patients with HCM.27–29 
In a single-centre study, we previously observed a higher 
concentration of PICP among mutation carriers.12 This was 
not replicated in the current multicentre cohort, and may 
be due to age differences in the control group. It may be 
that older samples with more advanced disease may display 
different biomarker profiles, including markers of neuro-
hormonal activation, myocyte injury and cardiac fibrosis. Of 
note, PICP concentrations were quite high in our control 
group. This may be in part due to the young age of muta-
tion-negative controls (mean age 17 years), raising the possi-
bility of bone turnover and growth during adolescence as 
potential confounder of PICP concentrations that is not 
fully accounted for by assessing BAP.30 In addition, phys-
ical exercise is a known source of bone turnover, and it has 
been shown in adolescent males (aged 15–17 years) that 
PICP increases with chronic aerobic/endurance training,31 
which may have influenced our study results. Lastly, given 
that apparently healthy controls were still selected from 
families with HCM participants, there may be other poten-
tial confounding factors at play, including possible unrec-
ognised genetic and familial determinants of circulating 
PICP.32
Galectin-3 is a potential mediator of cardiac fibrosis 
in experimental studies,33 and also reflects the degree 
of cardiac fibrosis in non-ischaemic cardiomyopathy as 
assessed by late gadolinium enhancement on CMR.34 
Circulating galectin-3 can be elevated years prior to clin-
ically apparent heart failure35; thus, we sought to inves-
tigate whether galectin-3 may be elevated early in the 
course of HCM. We did not find a difference in galectin-3 
among patients with HCM compared with genotype-neg-
ative related controls. These findings contrast with a prior 
case–control study showing that galectin-3 was higher 
in 40 patients with HCM compared with 35 unrelated 
healthy controls.36 This discrepancy may be due to differ-
ences in age, as our sample was over 20 years younger 
on average, compared with the prior case–control study. 
It is also important to note that galectin-3 levels are in 
part genetically determined,37 which may blunt poten-
tial differences among related individuals such as in our 
study. Among genotype-positive individuals, galectin-3 
Figure 1 Association of biomarker quartiles and 
echocardiographic traits. Panel A shows left atrial diameter 
across NT-proBNP and hsTnI quartiles; panel B shows left 
ventricular wall thickness; and panel C shows tissue Doppler 
velocity for global mitral annular velocity. p for trend <0.0001 
for all traits shown. hsTnI, high-sensitivity troponin I; LA, left 
atrial; LV, left ventricular; NT-proBNP, N-terminal pro-B-type 
natriuretic peptide. 
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was negatively correlated with E/A ratio, although we 
found no association with other measures of diastolic 
function or late gadolinium enhancement by CMR.
Lastly, we examined soluble ST2, an interleukin-1 
receptor family member that is upregulated in cardio-
myocytes in response to stress.38 Although patients with 
HCM had numerically higher soluble ST2 concentra-
tions, there was no statistical difference among groups.
In contrast to the paucity of studies on biomarkers 
in mutation carriers, numerous previous studies have 
examined cardiovascular biomarkers among patients 
with overt HCM. Our findings are congruent with others 
showing elevated natriuretic peptide and troponin 
concentrations in HCM, which in turn predict functional 
capacity and clinical prognosis among this patient popu-
lation.39–42 Among genotype-positive individuals, we also 
found that NT-proBNP and hsTnI were correlated with 
cardiac remodelling, including LA size, LV wall thickness, 
diastolic function as assessed by tissue Doppler mitral 
annular e' velocity, and regional fibrosis based on late 
gadolinium enhancement, similar to prior studies.39 43 44
Several additional limitations deserve mention. The 
utility of circulating biomarkers among mutation carriers 
without LVH remains unclear, particularly since we ascer-
tained biomarkers at a single timepoint among other-
wise relatively young, healthy individuals. Future studies 
should focus on serial measurements to examine whether 
biomarkers may be useful in detecting dynamic subclin-
ical cardiovascular remodelling as a potential screening 
strategy. We acknowledge that, despite a multicentre 
effort, our sample size is modest, and may preclude 
detection of smaller effect sizes. Based on prior studies 
on subjects with coronary artery disease,16 we ascertained 
biomarkers immediately after peak exercise, and again 
4 hours after maximal stress testing. It is possible that 
provoked changes with exercise might be better captured 
during recovery or later following exercise. Furthermore, 
it is possible that sustained, submaximal exercise, rather 
than maximal, symptom-limited exercise may be a more 
appropriate physiological stress to detect abnormalities 
in cardiac biomarker release.45
In sum, we showed that dynamic exercise testing exag-
gerated resting differences in natriuretic peptides and 
troponin elevations among individuals with overt HCM 
compared with controls. It is important to note that 
while we observed changes in NT-proBNP and hsTnI 
with exercise in overt HCM, the clinical implications of 
this finding remain unknown. The benefits of aerobic 
exercise in the general population are well-known, and 
whether this can be extended to patients with overt HCM 
is an active area of investigation.46 Despite the presence 
of altered cardiac structure and function by imaging, we 
found no differences in biomarker profiles of cardio-
vascular stress and fibrosis among preclinical mutation 
carriers without LVH compared with controls even after 
maximal exercise provocation. Our findings highlight 
that much remains to be elucidated with regard to the 
early phenotypes of sarcomeric gene mutations and the 
evolution of HCM. Continued investigation to identify 
pathways involved early in the disease processes, as well 
as serum biomarkers that reliably reflect their alteration, 
will yield valuable insights with regard to characterising 
disease development and targeting early preventive strat-
egies to at-risk individuals.
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